1. Home
  2. REBN vs LNAI Comparison

REBN vs LNAI Comparison

Compare REBN & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

HOLD

Current Price

$1.31

Market Cap

11.5M

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$2.16

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REBN
LNAI
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
12.4M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
REBN
LNAI
Price
$1.31
$2.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
105.1K
442.9K
Earning Date
04-22-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,094,628.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.54
N/A
52 Week Low
$0.91
$0.15
52 Week High
$3.09
$5.02

Technical Indicators

Market Signals
Indicator
REBN
LNAI
Relative Strength Index (RSI) 45.20 41.25
Support Level $0.91 $1.91
Resistance Level $2.02 $3.09
Average True Range (ATR) 0.15 0.22
MACD -0.00 -0.00
Stochastic Oscillator 19.48 4.63

Price Performance

Historical Comparison
REBN
LNAI

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: